Hemorrhagic complications associated with dabigatran use Academic Article uri icon

Overview

MeSH Major

  • Antithrombins
  • Benzimidazoles
  • Hemorrhage
  • beta-Alanine

abstract

  • The absence of a reversal agent for dabigatran raises concern for uncontrollable bleeding and death. Dabigatran's listed contraindications include active bleeding and a history of dabigatran hypersensitivity reaction. Wider use may result in bleeding rates higher than anticipated from clinical trials. Risks factors that may have contributed to bleeding in these patients include concomitant bleeding diathesis, antiplatelet agent use, renal insufficiency, advanced age, and fall risks.

publication date

  • November 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.3109/15563650.2012.721888

PubMed ID

  • 22970730

Additional Document Info

start page

  • 854

end page

  • 7

volume

  • 50

number

  • 9